Home > Insider Trading > Filing (0000914475-25-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1727606	Eiry Roberts	12780 El Camino Real San Diego CA 92130	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-01-31	2,769	$0.00	33,830	No	4	M	Direct
Common Stock	Disposition	2025-01-31	1,457	$152.80	32,373	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2025-01-31	2,769	$0.00	2,769	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,769			No	4	M	Direct

Footnotes

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
31,188 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,768 shares on January 31, 2023, vested as to 2,768 shares on January 31, 2024, vested as to 2,769 shares on January 31, 2025, and will vest as to 2,769 shares on January 31, 2026, subject to the terms and conditions of the award.